---
figid: PMC7643190__WJCO-11-761-g001
figlink: pmc/articles/PMC7643190/figure/F1/
number: F1
caption: 'Biomarkers, molecular pathways, existing and emerging therapeutic targets
  in colorectal cancer. A: Biomarkers and molecular pathways in colorectal cancer.
  Epidermal Growth Factor Receptor (EGFR) pathway: EGFR is a transmembrane receptor
  tyrosine kinase[]. EGF binding to the extracellular domain results in activation
  of down- stream intracellular signalling pathways such as RAS-RAF-MEK-MAPK, and
  the PI3K PKB mTOR pathway, amongst others, which favour cell proliferation and survival[-];
  Angiogenesis pathway: Vascular endothelial growth factors influence angiogenesis
  in health and disease via binding to the vascular endothelial growth factor receptor.
  Deregulated angiogenesis impacts on progression in solid tumours, thus providing
  potential anti-angiogenic therapies[]; Wnt pathway: The Wnt genes are vast family
  of highly conserved genes with wide ranging roles in development, cell proliferation
  and migration and tumorigenesis[]. Beta catenin accumulation in the cytoplasm and
  nucleus leads to cell proliferation. Excess beta catenin accumulation is prevented
  by its destruction by the “beta catenin destruction complex” (a multiprotein assembly
  containing adenomatous polyposis coli and GSK3). Wnt binding to its receptor frizzled
  leads to impaired function of the Beta catenin destruction complex and hence beta
  catenin accumulation and cell proliferation[]. Mutations in adenomatous polyposis
  coli prevent the formation of the beta catenin complex, and therefore allow beta
  catenin accumulation and cell proliferation. PI3K inhibits the function of GSK3[],
  thereby impairing the beta catenin destruction complex, hence contributing to the
  tumorigenic accumulation of beta catenin. B: Existing and emerging therapeutic targets
  in colorectal cancer pathways. B: Cetuximab and Panitumumab are monoclonal antibodies
  targeting the EGFR, thus blocking activation of downstream signalling pathways.
  Mutated and constitutively active downstream effectors (such as RAS and RAF) confer
  resistance to EGFR blockade. Erlotinib and gefitinib are EGFR Tyrosine kinase inhibitors
  and are associated with improved PFS when combined to Bevacizumab in the DREAM trial[].
  Vemurafenib is a RAF inhibitor which in combination with EGFR blockade[] has shown
  marked responses in some case reports[]. Selumetinib is a MEK kinase inhibitor showing
  tumour response in some patients with KRAS mutant colorectal cancers progressing
  on Oxaliplatin[]. Regorafenib inhibits is a multi-kinase inhibitor[], with OS benefit
  in randomised double blind control trials[,]. Bevacizumab is a Monoclonal antibody
  against VEGFA with the most prominently established role in the treatment of metastatic
  colorectal cancer. Famitinib is a multiple tyrosine kinase inhibitor and targets
  the vascular endothelial growth factor receptor tyrosine kinase. Monoclonal antibodies
  targeting the VEGF receptors are also under investigation[]. EGF: Epidermal Growth
  Factor; EGFR: Epidermal Growth Factor Receptor; EGFR TKI: Epidermal Growth Factor
  Receptor tyrosine kinase inhibitor; K-ras: K-Ras protein (product of the proto-oncogene
  KRAS); BRAF: BRAF protein (product of the proto-oncogene BRAF; MEK: Mitogen activated
  protein kinase which activates MAPK (mitogen-activated protein kinase); VEGF: Vascular
  endothelial growth factor; VEGFR: Vascular endothelial growth factor receptor; PI3K:
  phosphoinositide 3-kinase; PKB: Protein kinase B; mTOR: Mammalian target of Rapamycin;
  Wnt: Wnt protein product of proto-oncogne Wnt; Frizzled Receptor: Receptor for Wnt;
  APC: Protein product of the tumour suppressor gene APC (Adenomatous polyposis coli);
  GSK3: Glycogen synthase kinase 3.'
pmcid: PMC7643190
papertitle: 'Colorectal liver metastases: Current management and future perspectives.'
reftext: Jack Martin, et al. World J Clin Oncol. 2020 Oct 24;11(10):761-808.
pmc_ranked_result_index: '106235'
pathway_score: 0.9127047
filename: WJCO-11-761-g001.jpg
figtitle: Biomarkers, molecular pathways, existing and emerging therapeutic targets
  in colorectal cancer
year: '2020'
organisms: Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7643190__WJCO-11-761-g001.html
  '@type': Dataset
  description: 'Biomarkers, molecular pathways, existing and emerging therapeutic
    targets in colorectal cancer. A: Biomarkers and molecular pathways in colorectal
    cancer. Epidermal Growth Factor Receptor (EGFR) pathway: EGFR is a transmembrane
    receptor tyrosine kinase[]. EGF binding to the extracellular domain results in
    activation of down- stream intracellular signalling pathways such as RAS-RAF-MEK-MAPK,
    and the PI3K PKB mTOR pathway, amongst others, which favour cell proliferation
    and survival[-]; Angiogenesis pathway: Vascular endothelial growth factors influence
    angiogenesis in health and disease via binding to the vascular endothelial growth
    factor receptor. Deregulated angiogenesis impacts on progression in solid tumours,
    thus providing potential anti-angiogenic therapies[]; Wnt pathway: The Wnt genes
    are vast family of highly conserved genes with wide ranging roles in development,
    cell proliferation and migration and tumorigenesis[]. Beta catenin accumulation
    in the cytoplasm and nucleus leads to cell proliferation. Excess beta catenin
    accumulation is prevented by its destruction by the “beta catenin destruction
    complex” (a multiprotein assembly containing adenomatous polyposis coli and GSK3).
    Wnt binding to its receptor frizzled leads to impaired function of the Beta catenin
    destruction complex and hence beta catenin accumulation and cell proliferation[].
    Mutations in adenomatous polyposis coli prevent the formation of the beta catenin
    complex, and therefore allow beta catenin accumulation and cell proliferation.
    PI3K inhibits the function of GSK3[], thereby impairing the beta catenin destruction
    complex, hence contributing to the tumorigenic accumulation of beta catenin. B:
    Existing and emerging therapeutic targets in colorectal cancer pathways. B: Cetuximab
    and Panitumumab are monoclonal antibodies targeting the EGFR, thus blocking activation
    of downstream signalling pathways. Mutated and constitutively active downstream
    effectors (such as RAS and RAF) confer resistance to EGFR blockade. Erlotinib
    and gefitinib are EGFR Tyrosine kinase inhibitors and are associated with improved
    PFS when combined to Bevacizumab in the DREAM trial[]. Vemurafenib is a RAF inhibitor
    which in combination with EGFR blockade[] has shown marked responses in some case
    reports[]. Selumetinib is a MEK kinase inhibitor showing tumour response in some
    patients with KRAS mutant colorectal cancers progressing on Oxaliplatin[]. Regorafenib
    inhibits is a multi-kinase inhibitor[], with OS benefit in randomised double blind
    control trials[,]. Bevacizumab is a Monoclonal antibody against VEGFA with the
    most prominently established role in the treatment of metastatic colorectal cancer.
    Famitinib is a multiple tyrosine kinase inhibitor and targets the vascular endothelial
    growth factor receptor tyrosine kinase. Monoclonal antibodies targeting the VEGF
    receptors are also under investigation[]. EGF: Epidermal Growth Factor; EGFR:
    Epidermal Growth Factor Receptor; EGFR TKI: Epidermal Growth Factor Receptor tyrosine
    kinase inhibitor; K-ras: K-Ras protein (product of the proto-oncogene KRAS); BRAF:
    BRAF protein (product of the proto-oncogene BRAF; MEK: Mitogen activated protein
    kinase which activates MAPK (mitogen-activated protein kinase); VEGF: Vascular
    endothelial growth factor; VEGFR: Vascular endothelial growth factor receptor;
    PI3K: phosphoinositide 3-kinase; PKB: Protein kinase B; mTOR: Mammalian target
    of Rapamycin; Wnt: Wnt protein product of proto-oncogne Wnt; Frizzled Receptor:
    Receptor for Wnt; APC: Protein product of the tumour suppressor gene APC (Adenomatous
    polyposis coli); GSK3: Glycogen synthase kinase 3.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - VEGFD
  - VEGFB
  - PGF
  - VEGFA
  - VEGFC
  - EGF
  - WNT1
  - WNT5A
  - WNT6
  - WNT7A
  - WNT8A
  - WNT8B
  - WNT10B
  - WNT2B
  - WNT16
  - WNT2
  - WNT3
  - WNT7B
  - WNT11
  - WNT9A
  - WNT9B
  - WNT4
  - WNT10A
  - WNT5B
  - WNT3A
  - FZD5
  - FZD7
  - FZD9
  - FZD2
  - FZD3
  - FZD1
  - FZD4
  - FZD6
  - FZD8
  - FZD10
  - EGFR
  - FLT1
  - FLT4
  - KDR
  - KRAS
  - CTNNB1
  - BRAF
  - AKT1
  - MAP2K1
  - MAP2K2
  - APC
  - MTOR
  - GSK3A
  - GSK3B
  - MAPK14
  - MAPK3
  - MAPK8
  - MAPK11
  - MAPK13
  - MAPK12
  - MAPK1
  - MAPK9
  - MAPK10
  - MAK
  - TXK
  - PIK3CA
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3CB
  - PIK3CD
  - PIK3R5
  - PIK3R6
  - Famitinib
  - Erlotinib
  - gefitinib
  - Vemurafenib
  - Regorafenib
  - Selumetinib
genes:
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: EGF
  symbol: EGF
  source: hgnc_symbol
  hgnc_symbol: EGF
  entrez: '1950'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT1
  entrez: '7471'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT5A
  entrez: '7474'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT6
  entrez: '7475'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT7A
  entrez: '7476'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT8A
  entrez: '7478'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT8B
  entrez: '7479'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT10B
  entrez: '7480'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT2B
  entrez: '7482'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT16
  entrez: '51384'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT2
  entrez: '7472'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT3
  entrez: '7473'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT7B
  entrez: '7477'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT11
  entrez: '7481'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT9A
  entrez: '7483'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT9B
  entrez: '7484'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT4
  entrez: '54361'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT10A
  entrez: '80326'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT5B
  entrez: '81029'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT3A
  entrez: '89780'
- word: Frizzled
  symbol: Frizzled
  source: bioentities_symbol
  hgnc_symbol: FZD5
  entrez: '7855'
- word: Frizzled
  symbol: Frizzled
  source: bioentities_symbol
  hgnc_symbol: FZD7
  entrez: '8324'
- word: Frizzled
  symbol: Frizzled
  source: bioentities_symbol
  hgnc_symbol: FZD9
  entrez: '8326'
- word: Frizzled
  symbol: Frizzled
  source: bioentities_symbol
  hgnc_symbol: FZD2
  entrez: '2535'
- word: Frizzled
  symbol: Frizzled
  source: bioentities_symbol
  hgnc_symbol: FZD3
  entrez: '7976'
- word: Frizzled
  symbol: Frizzled
  source: bioentities_symbol
  hgnc_symbol: FZD1
  entrez: '8321'
- word: Frizzled
  symbol: Frizzled
  source: bioentities_symbol
  hgnc_symbol: FZD4
  entrez: '8322'
- word: Frizzled
  symbol: Frizzled
  source: bioentities_symbol
  hgnc_symbol: FZD6
  entrez: '8323'
- word: Frizzled
  symbol: Frizzled
  source: bioentities_symbol
  hgnc_symbol: FZD8
  entrez: '8325'
- word: Frizzled
  symbol: Frizzled
  source: bioentities_symbol
  hgnc_symbol: FZD10
  entrez: '11211'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: KRAS
  symbol: KRAS
  source: hgnc_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: Betacatenin
  symbol: BCATENIN
  source: bioentities_symbol
  hgnc_symbol: CTNNB1
  entrez: '1499'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PKB
  symbol: PKB
  source: hgnc_alias_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: АРС
  symbol: APC
  source: hgnc_symbol
  hgnc_symbol: APC
  entrez: '324'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: GSK3
  symbol: GSK3
  source: bioentities_symbol
  hgnc_symbol: GSK3A
  entrez: '2931'
- word: GSK3
  symbol: GSK3
  source: bioentities_symbol
  hgnc_symbol: GSK3B
  entrez: '2932'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: МАРК
  symbol: MAK
  source: hgnc_symbol
  hgnc_symbol: MAK
  entrez: '4117'
- word: Beta-catenin
  symbol: BCATENIN
  source: bioentities_symbol
  hgnc_symbol: CTNNB1
  entrez: '1499'
- word: EGF
  symbol: EGF
  source: hgnc_symbol
  hgnc_symbol: EGF
  entrez: '1950'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT1
  entrez: '7471'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT5A
  entrez: '7474'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT6
  entrez: '7475'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT7A
  entrez: '7476'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT8A
  entrez: '7478'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT8B
  entrez: '7479'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT10B
  entrez: '7480'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT2B
  entrez: '7482'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT16
  entrez: '51384'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT2
  entrez: '7472'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT3
  entrez: '7473'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT7B
  entrez: '7477'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT11
  entrez: '7481'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT9A
  entrez: '7483'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT9B
  entrez: '7484'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT4
  entrez: '54361'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT10A
  entrez: '80326'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT5B
  entrez: '81029'
- word: Wnt
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT3A
  entrez: '89780'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: Frizzled
  symbol: Frizzled
  source: bioentities_symbol
  hgnc_symbol: FZD5
  entrez: '7855'
- word: Frizzled
  symbol: Frizzled
  source: bioentities_symbol
  hgnc_symbol: FZD7
  entrez: '8324'
- word: Frizzled
  symbol: Frizzled
  source: bioentities_symbol
  hgnc_symbol: FZD9
  entrez: '8326'
- word: Frizzled
  symbol: Frizzled
  source: bioentities_symbol
  hgnc_symbol: FZD2
  entrez: '2535'
- word: Frizzled
  symbol: Frizzled
  source: bioentities_symbol
  hgnc_symbol: FZD3
  entrez: '7976'
- word: Frizzled
  symbol: Frizzled
  source: bioentities_symbol
  hgnc_symbol: FZD1
  entrez: '8321'
- word: Frizzled
  symbol: Frizzled
  source: bioentities_symbol
  hgnc_symbol: FZD4
  entrez: '8322'
- word: Frizzled
  symbol: Frizzled
  source: bioentities_symbol
  hgnc_symbol: FZD6
  entrez: '8323'
- word: Frizzled
  symbol: Frizzled
  source: bioentities_symbol
  hgnc_symbol: FZD8
  entrez: '8325'
- word: Frizzled
  symbol: Frizzled
  source: bioentities_symbol
  hgnc_symbol: FZD10
  entrez: '11211'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: TKI
  symbol: TKL
  source: hgnc_alias_symbol
  hgnc_symbol: TXK
  entrez: '7294'
- word: KRAS
  symbol: KRAS
  source: hgnc_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: Betacatenin
  symbol: BCATENIN
  source: bioentities_symbol
  hgnc_symbol: CTNNB1
  entrez: '1499'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PKB
  symbol: PKB
  source: hgnc_alias_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: АРС
  symbol: APC
  source: hgnc_symbol
  hgnc_symbol: APC
  entrez: '324'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: GSK3
  symbol: GSK3
  source: bioentities_symbol
  hgnc_symbol: GSK3A
  entrez: '2931'
- word: GSK3
  symbol: GSK3
  source: bioentities_symbol
  hgnc_symbol: GSK3B
  entrez: '2932'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: МАРК
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: МАРК
  symbol: MAK
  source: hgnc_symbol
  hgnc_symbol: MAK
  entrez: '4117'
- word: Beta-catenin
  symbol: BCATENIN
  source: bioentities_symbol
  hgnc_symbol: CTNNB1
  entrez: '1499'
chemicals:
- word: Famitinib
  source: MESH
  identifier: C584390
- word: Erlotinib
  source: MESH
  identifier: C400278
- word: gefitinib
  source: MESH
  identifier: C419708
- word: Vemurafenib
  source: MESH
  identifier: C551177
- word: Regorafenib
  source: MESH
  identifier: C559147
- word: Selumetinib
  source: MESH
  identifier: C517975
diseases: []
figid_alias: PMC7643190__F1
redirect_from: /figures/PMC7643190__F1
figtype: Figure
---
